X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1453) 1453
b7-h1 antigen - antagonists & inhibitors (1137) 1137
immunotherapy (836) 836
programmed cell death 1 receptor - antagonists & inhibitors (757) 757
oncology (745) 745
animals (607) 607
female (545) 545
cancer (540) 540
b7-h1 antigen - immunology (493) 493
b7-h1 antigen - metabolism (460) 460
male (398) 398
mice (368) 368
pd-l1 (351) 351
antibodies, monoclonal - therapeutic use (350) 350
tumors (335) 335
immunology (333) 333
immunotherapy - methods (315) 315
programmed cell death 1 receptor - immunology (315) 315
nivolumab (307) 307
pd-1 (302) 302
ctla-4 antigen - antagonists & inhibitors (290) 290
apoptosis (288) 288
lymphocytes (283) 283
middle aged (279) 279
antineoplastic agents - therapeutic use (276) 276
antineoplastic agents, immunological - therapeutic use (276) 276
pd-l1 protein (272) 272
aged (268) 268
chemotherapy (265) 265
cell line, tumor (255) 255
expression (254) 254
melanoma (250) 250
b7-h1 antigen - genetics (241) 241
treatment outcome (241) 241
immune checkpoint (239) 239
neoplasms - immunology (237) 237
ligands (231) 231
pembrolizumab (220) 220
pd-1 protein (218) 218
lymphocytes t (211) 211
lung neoplasms - drug therapy (210) 210
programmed cell death 1 receptor - metabolism (208) 208
adult (200) 200
open-label (197) 197
care and treatment (195) 195
t cells (192) 192
blockade (190) 190
neoplasms - drug therapy (189) 189
metastasis (188) 188
lung cancer (184) 184
molecular targeted therapy (181) 181
carcinoma, non-small-cell lung - drug therapy (176) 176
prognosis (175) 175
therapy (174) 174
patients (173) 173
cancer therapies (172) 172
antineoplastic agents - pharmacology (166) 166
ipilimumab (162) 162
mice, inbred c57bl (162) 162
antibodies, monoclonal - pharmacology (161) 161
t-lymphocytes - immunology (155) 155
research (154) 154
safety (153) 153
clinical trials (146) 146
mutation (139) 139
neoplasms - therapy (139) 139
t-cells (139) 139
antigens (138) 138
cell death (138) 138
biomarkers (137) 137
aged, 80 and over (136) 136
b7-h1 (135) 135
survival (134) 134
immune system (133) 133
lung neoplasms - pathology (133) 133
antibodies, monoclonal, humanized - therapeutic use (132) 132
clinical trials as topic (131) 131
analysis (130) 130
ctla-4 antigen - immunology (128) 128
gene expression (127) 127
lung neoplasms - immunology (127) 127
docetaxel (125) 125
antineoplastic combined chemotherapy protocols - therapeutic use (123) 123
pd-1 blockade (122) 122
activation (121) 121
cytotoxicity (120) 120
health aspects (119) 119
pd-l1 expression (119) 119
immunohistochemistry (118) 118
dendritic cells (117) 117
disease models, animal (116) 116
signal transduction - drug effects (116) 116
tumor microenvironment (116) 116
cd8-positive t-lymphocytes - immunology (115) 115
metastases (115) 115
antibodies (113) 113
antibody (113) 113
medical prognosis (111) 111
medical research (111) 111
immune response (109) 109
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1622) 1622
French (20) 20
Chinese (9) 9
Czech (7) 7
German (5) 5
Italian (2) 2
Japanese (2) 2
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PloS one, ISSN 1932-6203, 12/2013, Volume 8, Issue 12, p. e83139
... synapse between T cells and antigen-presenting cells (APCs). What remains incompletely understood is how CD28 leads to the activation of effector T cells (Teff... 
IN-VITRO | ACTIVATION | HOMEOSTASIS | DENDRITIC CELLS | TOLERANCE | MULTIDISCIPLINARY SCIENCES | EXTRINSIC CONTROL | ANTI-CD28 ANTIBODY | UP-REGULATION | CUTTING EDGE | LYMPHOCYTES | B7-1 Antigen - antagonists & inhibitors | Cell Communication - immunology | B7-2 Antigen - genetics | B7-1 Antigen - genetics | Dendritic Cells - immunology | Humans | Molecular Targeted Therapy | T-Lymphocytes, Regulatory - immunology | T-Lymphocytes, Cytotoxic - drug effects | CD28 Antigens - genetics | Protein Binding - drug effects | CD28 Antigens - antagonists & inhibitors | T-Lymphocytes, Regulatory - cytology | Dendritic Cells - drug effects | B7-2 Antigen - immunology | T-Lymphocytes, Cytotoxic - immunology | Gene Expression | B7-2 Antigen - antagonists & inhibitors | B7-1 Antigen - immunology | Antibodies, Monoclonal - pharmacology | CTLA-4 Antigen - genetics | CD28 Antigens - immunology | CTLA-4 Antigen - immunology | B7-H1 Antigen - genetics | B7-H1 Antigen - immunology | Cell Movement - drug effects | T-Lymphocytes, Regulatory - drug effects | B7-H1 Antigen - antagonists & inhibitors | Lymphocyte Activation - drug effects | Cell Communication - drug effects | Dendritic Cells - cytology | CTLA-4 Antigen - antagonists & inhibitors | T-Lymphocytes, Cytotoxic - cytology | Viral antibodies | Antibodies | Antigens | B cells | T cells | Motility | Transplants & implants | Calcium | Blocking antibodies | Homeostasis | Effector cells | Immunological synapses | Lymphocytes T | Kinases | CD28 antigen | T-cell receptor | CTLA-4 protein | Cell activation | Immunology | Lymphocytes | Dwell time | Cell cycle | Cytokines | Immunoregulation | CD80 antigen | T cell receptors | Costimulator | Microscopy | Antigen-presenting cells | PD-L1 protein | Ligands | Cell migration | Synapses | Apoptosis | Life Sciences | Human health and pathology
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 2016, Volume 54, pp. 139 - 148
Journal Article
European journal of immunology, ISSN 0014-2980, 2011, Volume 41, Issue 2, pp. 413 - 424
During infection, TLR agonists are released and trigger mature as well as differentiating innate immune cells. Early encounter with TLR agonists (R848; LPS)... 
Tolerance | STAT‐3 | TLR | PD‐L1 | PD-L1 | STAT-3 | MYCOBACTERIUM-TUBERCULOSIS | ALLOGRAFT-REJECTION | HUMAN DENDRITIC CELLS | IFN-GAMMA | TRANSPLANT TOLERANCE | IMMUNOLOGY | CUTTING EDGE | IMMUNE-RESPONSES | REGULATORY T-CELLS | B7 FAMILY | DIFFERENTIATION | T-Lymphocyte Subsets - immunology | Antigen-Presenting Cells - cytology | Immune Tolerance - physiology | Monocytes - cytology | Dendritic Cells - immunology | Humans | Mitogen-Activated Protein Kinase 3 - antagonists & inhibitors | STAT Transcription Factors - metabolism | Monocytes - immunology | Antigens, CD - metabolism | Lipopolysaccharide Receptors - metabolism | Lymphocyte Culture Test, Mixed | T-Lymphocytes, Regulatory - immunology | Signal Transduction - immunology | Interleukin-4 - pharmacology | Interleukin-10 - metabolism | Histocompatibility Antigens Class II - metabolism | p38 Mitogen-Activated Protein Kinases - metabolism | Phosphorylation - drug effects | Interleukin-6 - metabolism | STAT3 Transcription Factor - metabolism | Antigen-Presenting Cells - metabolism | B7-H1 Antigen | Gene Expression Regulation - immunology | Antigen-Presenting Cells - drug effects | Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors | Granulocyte-Macrophage Colony-Stimulating Factor - pharmacology | Imidazoles - pharmacology | Antigen-Presenting Cells - immunology | Toll-Like Receptors - agonists | Monocytes - drug effects | Cell Differentiation - immunology | Mitogen-Activated Protein Kinase 3 - metabolism | Cell Differentiation - drug effects | Antigens, CD1 - metabolism | p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors | Dendritic Cells - cytology | Protein Kinase Inhibitors - pharmacology | STAT Transcription Factors - antagonists & inhibitors | STAT3 Transcription Factor - antagonists & inhibitors | Mitogen-Activated Protein Kinase 1 - metabolism | Medical research | Rodents
Journal Article
Journal of hematology and oncology, ISSN 1756-8722, 2017, Volume 10, Issue 1, pp. 103 - 16
... antigens and kill the cancer cells. The whole process is elegantly explained by Chen and Mellman with the concept of the cancer-immunity cycle, which consists... 
PD-L1 | PD-L2 | Hematologic malignancies | CTLA-4 | Immune checkpoint | PD-1 | MULTIPLE-MYELOMA | PD-1 BLOCKADE | BRENTUXIMAB VEDOTIN | ACUTE MYELOID-LEUKEMIA | CD8(+) T-CELLS | B-CELL LYMPHOMA | ONCOLOGY | CLASSICAL HODGKIN LYMPHOMA | DEATH LIGAND 1 | HEMATOLOGY | NF-KAPPA-B | Tumor Escape - drug effects | B7-H1 Antigen - physiology | Humans | Hepatitis A Virus Cellular Receptor 2 - physiology | Neoplasm Proteins - antagonists & inhibitors | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Clinical Trials as Topic | Antigens, CD - drug effects | Programmed Cell Death 1 Receptor - physiology | Molecular Targeted Therapy | Antigen-Presenting Cells - immunology | Biomarkers, Tumor | Patient Selection | Antineoplastic Agents, Immunological - adverse effects | Hepatitis A Virus Cellular Receptor 2 - antagonists & inhibitors | B7-H1 Antigen - antagonists & inhibitors | Multicenter Studies as Topic | Antineoplastic Agents, Immunological - therapeutic use | Lymphocyte Activation - drug effects | Hematologic Neoplasms - drug therapy | Antigens, CD - physiology | CTLA-4 Antigen - antagonists & inhibitors | CTLA-4 Antigen - physiology | PD-1 protein | Lung cancer | Clinical trials | Recovery of function | Cytotoxicity | Biology | CD223 antigen | Myeloma | Myelodysplastic syndrome | Proteins | CTLA-4 protein | Immunology | Lymphocytes | Immunotherapy | Janus kinase 2 | Antigens | Immunoglobulins | Immune response | Hematology | Myeloid leukemia | Melanoma | Immunosurveillance | T cell receptors | Lymphoma | PD-L1 protein | Biomarkers | Ligands | Lymphomas | Acute myeloid leukemia | Binding sites | Hodgkin's disease | Apoptosis
Journal Article
Current opinion in immunology, ISSN 0952-7915, 2015, Volume 33, pp. 23 - 35
Journal Article
Journal of thoracic oncology, ISSN 1556-0864, 2015, Volume 10, Issue 6, pp. 910 - 923
Epidermal growth factor receptor (EGFR) mutation status was reported to be associated with programmed death-ligand 1 (PD-L1) expression. However, the molecular... 
PD-L1 | NSCLC | PD-1 | EGFR | Tyrosine kinase inhibitors | LUNG | CELLS | B7-H1 EXPRESSION | DEATH-LIGAND 1 | MELANOMA | ONCOLOGY | PATHWAY | IMMUNOTHERAPY | RESPIRATORY SYSTEM | POOR-PROGNOSIS | GROWTH | INHIBITORS | Tumor Escape - drug effects | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Sequence Deletion | Up-Regulation | Exons | Humans | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Molecular Targeted Therapy | Receptor, Epidermal Growth Factor - metabolism | T-Lymphocytes - pathology | Lung Neoplasms - genetics | Receptor, Epidermal Growth Factor - immunology | Lung Neoplasms - enzymology | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Programmed Cell Death 1 Receptor - metabolism | B7-H1 Antigen - genetics | B7-H1 Antigen - immunology | Carcinoma, Non-Small-Cell Lung - immunology | B7-H1 Antigen - metabolism | Lung Neoplasms - immunology | Apoptosis - immunology | B7-H1 Antigen - antagonists & inhibitors | Interferon-gamma - immunology | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | T-Lymphocytes - immunology | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Programmed Cell Death 1 Receptor - immunology | Programmed Cell Death 1 Receptor - genetics | Interferon-gamma - biosynthesis
Journal Article
Journal Article
Gut, ISSN 0017-5749, 02/2018, Volume 67, Issue 2, pp. 320 - 332
ObjectiveLimited efficacy of immune checkpoint inhibitors in pancreatic ductal adenocarcinoma (PDAC) has prompted investigation into combination therapy. We... 
INTERLEUKINS | IMMUNOTHERAPY | PANCREATIC CANCER | MULTIPLE-MYELOMA | INTERFERON-ALPHA | ACTIVATION | ADENOCARCINOMA | SILTUXIMAB | MONOCLONAL-ANTIBODY | MICE | SUPPRESSOR-CELLS | INTERLEUKIN-6 | GASTROENTEROLOGY & HEPATOLOGY | T-CELLS | Antineoplastic Agents, Immunological - administration & dosage | Interleukin-6 - antagonists & inhibitors | Pancreatic Neoplasms - metabolism | Humans | Actins - metabolism | Carcinoma, Pancreatic Ductal - metabolism | STAT Transcription Factors - metabolism | Janus Kinases - metabolism | L-Selectin - metabolism | Pancreatic Neoplasms - drug therapy | Th1 Cells - metabolism | Pancreatic Stellate Cells - immunology | Hyaluronan Receptors - metabolism | Female | Lymphocytes, Tumor-Infiltrating - metabolism | Carcinoma, Pancreatic Ductal - immunology | Interleukin-6 - metabolism | Disease Models, Animal | Mice, Inbred C57BL | Survival Rate | B7-H1 Antigen - immunology | Disease Progression | Tumor Microenvironment - immunology | Xenograft Model Antitumor Assays | Carcinoma, Pancreatic Ductal - drug therapy | B7-H1 Antigen - metabolism | Animals | B7-H1 Antigen - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pancreatic Neoplasms - immunology | Interleukin-6 - immunology | Mice | Pancreatic Stellate Cells - metabolism | Adenocarcinoma | Immunohistochemistry | Flow cytometry | Animal models | Transcription | CD8 antigen | Multiple myeloma | Smooth muscle | Lymphocytes T | Kinases | Metastases | Interleukin 6 | Lymphocytes | Actin | CD44 antigen | Immunotherapy | Fibroblasts | BRCA2 protein | Stellate cells | Cytokines | Stroma | CD62L protein | CD4 antigen | Immune checkpoint | Antibiotics | Pancreatic cancer | Medical prognosis | PD-L1 protein | Ligands | Genetic engineering | Apoptosis | PD-L1 | pancreatic cancer | IL-6
Journal Article